Anti-Human/Mouse IL-10 (Clone JES3-9D7) – Recombinant in vivo functional grade

Recombinant human IL-10

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

JES3-9D7 activity is directed against human and mouse interleukin-10 (IL-10).

Interleukin-10 (IL-10) is a homodimeric, anti-inflammatory cytokine of 17-21 kD¹. It was initially discovered because of its ability to inhibit the synthesis of various pro-inflammatory cytokines produced by T helper 1 (Th1) cells. It plays a vital role in regulating the immune response and inflammation². IL-10 has diverse effects and can either suppress or promote immune responses based on the circumstances. Its anti-inflammatory properties include inhibiting the activity of Th1 cells, natural killer (NK) cells, and macrophages. These cells play a role in clearing pathogens but can also lead to tissue damage^3-7. IL-10 supports the activation of B-cells and CD8+ T-cells and is involved in peripheral T-cell tolerance to allergens, autoantigens, transplantation antigens, and tumor antigens⁸.

The dysregulation of IL-10 has been linked to an increased risk of autoimmune diseases and enhanced immunopathology in response to infection. In mice, the absence of IL-10 has been shown to cause inflammation and pain by COX activation, leading to dysfunctions in the vascular endothelial and cardiac systems. Studies in which IL-10 was knocked out suggest that this cytokine plays a crucial role in counteracting the hyperactive immune response in the intestinal tract. It has been reported that the treatment of Crohn’s disease patients with recombinant IL-10-producing bacteria has been beneficial. IL- 10 is associated with certain diseases such as Graft-Versus-Host Disease and Human Immunodeficiency Virus Type 1⁹.

JES3-9D7 is a monoclonal antibody that specifically targets and neutralizes human and mouse IL-10. It has been extensively studied for its ability to inhibit the biological activity of IL-10 and its potential therapeutic applications^10,11.

IL-10 is produced by various immune cells, including T cells, B cells, macrophages, and dendritic cells.

IL-10R (CDw210)

1. Isac L, Jiquan S. Interleukin 10 promotor gene polymorphism in the pathogenesis of psoriasis. Acta Dermatovenerol Alp Pannonica Adriat. 2019;28(3):119-123.
2. Trinchieri G. Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med.2007;204(2):239-243.
3. Ng THS, Britton GJ, Hill EV, Verhagen J, Burton BR, Wraith DC. Regulation of adaptive immunity; the role of interleukin-10. Front Immunol. 2013;4:129.
4. de Vries JE. Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med. 1995;27(5):537-541.
5. Cai G, Kastelein RA, Hunter CA. IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. Eur J Immunol. 1999;29(9):2658-2665.
6. Kubo M, Motomura Y. Transcriptional regulation of the anti-inflammatory cytokine IL-10 in acquired immune cells. Front Immunol. 2012;3:275.
7. Zhou X, Schmidtke P, Zepp F, Meyer CU. Boosting interleukin-10 production: therapeutic effects and mechanisms. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5(4):465-475.
8. Jonuleit H, Adema G, Schmitt E. Immune regulation by regulatory T cells: implications for transplantation. Transpl Immunol. 2003;11(3-4):267-276.
9. Geginat J, Larghi P, Paroni M, et al. The light and the dark sides of Interleukin-10 in immune- mediated diseases and cancer. Cytokine Growth Factor Rev. 2016;30:87-93.
10. Ho AS, Liu Y, Khan TA, Hsu DH, Bazan JF, Moore KW. A receptor for interleukin 10 is related to interferon receptors. Proc Natl Acad Sci U S A. 1993;90(23):11267-11271.
11. Sabat R, Seifert M, Volk HD, Glaser RW. Neutralizing murine monoclonal anti-interleukin-10 antibodies enhance binding of antibodies against a different epitope. Mol Immunol. 1996;33(14):1103-1111.
12. Abrams JS, Roncarolo MG, Yssel H, Andersson U, Gleich GJ, Silver JE. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev. 1992;127:5-24.
13. Gotlieb WH, Abrams JS, Watson JM, Velu TJ, Berek JS, Martínez-Maza O. Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine. 1992;4(5):385-390.
14. Yssel H, De Waal Malefyt R, Roncarolo MG, et al. IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells. J Immunol. 1992;149(7):2378-2384.
15. Burdin N, Van Kooten C, Galibert L, et al. Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J Immunol. 1995;154(6):2533-2544.
16. Akdis CA, Blesken T, Akdis M, Wüthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest. 1998;102(1):98-106.
17. Smith DR, Kunkel SL, Burdick MD, et al. Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol. 1994;145(1):18-25.